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Rezumat
Diagnosticul fenotipic sau genotipic al hemocroma-
tozei?
Hemocromatoza ereditară (HE) este o afecţiune genetică 
determinată de supraîncărcarea cu fi er, bazată pe mutaţia 
genei HFE, clasifi cată în 4 genotipuri, cel mai răspândit 
fi ind genotipul I (90%). Implicarea fi catului este cea mai 
frecventă abnormalitate în HE, iar studiile dovedesc că 
indicele hepatic al fi erului poate fi  în limitele normei la 
persoanele cu HE, totodată fi ind sporit la cei cu sindroame 
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secundare de supraîncărcare cu fi er. În această publicaţie 
propunem spre discuţie care, totuşi, ar fi  cele mai efi ciente 
metode: genotipice ori fenotipice în stabilirea HE, bazându-
se pe un caz clinic real.
Cuvinte-cheie: hemocromatoză, diagnostic
Резюмe 
Фенотипичное и генотипичное определение гемо-
кроматоза
Наследственный  гемохроматоз  – аутосомно-
рецессивное заболевание, частота распространенно-
сти которого 1 человек на 200, относится к заболевани-
ям, при которых относительно несложно выявить гене-
тический дефект (HFE-гена). Несмотря на полиморф-
ность гемохроматоза, поражение печени встречается 
в 100% случаев, которое может регистрироваться 
как при случайном обследовании по поводу повышения 
уровня трансаминаз, так и при дебюте портальной 
гипертензии на фоне уже сформировавшегося цирроза 
печени. До генетического тестирования существует 
вполне пригодный метод обследования населения пу-
тем чувствительного фенотипического скрининга: 
определения насыщения трансферрина, количество 
сывороточного железа, уровень ферритина. 
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Introduction
HH includes a variety of chronic iron overload 
syndromes of genetic origin. They can be classified 
into 4 groups from type 1 to type 4 according to 
genetic mutations [1, 2]. HH is the most genetic 
condition known in people of European descent. It 
is estimated that one in 200 people with European 
ancestry have the typical genetic pattern associate 
with this condition [6, 7]. If the disease is defined 
based on symptoms, the prevalence would be much 
lower, and because the symptoms may be nonspe-
cific, it is more difficult to assess the prevalence of 
symptomatic hemochromatosis [3, 8]. 
Classic HH is an autosomal recessive iron-over-
load disorder associated with mutation of the HFE 
gene, which is located on chromosome 6; in most ca-
ses the mutation is a single-base change that results 
in the substitution of tyrosine for cysteine at position 
282 of the HFE protein (C282Y) [1, 2, 7].  Homozygo-
sity for the C282Y mutation is now found in approxi-
mately 5 of every 1000 persons of northern European 
descent — a prevalence 10 times that of cystic fibrosis 
genotypes [3,5]. All persons who are homozygous for 
the C282Y mutation are genetically predisposed to a 
chain of events that may culminate in severe damage 
to multiple organs, but it is currently impossible to 
predict whether, and to what extent, the mutation 
will be phenotypically expressed [4, 7]. 
Most of the debate regarding hemochromato-
sis centers on its phenotypic or genotypic diagnosis. 
The genetic defect, which caused no serious obstacle 
to reproduction and may phenotypic and genetic 
features have conferred some advantages, was pas-
sed on and spread by population migration [7, 8]. 
The genetic aspect of hemochromatosis
Human iron homeostasis depends on the co-
ordinated functions of numerous genes, the precise 
roles of which are, in many cases, still obscure.  The 
major-histocompatibility- complex class I–like pro-
tein, HFE, which has an ancestral peptide-binding 
groove that is too narrow for antigen presentation, 
is also incapable of binding iron [5, 6, 8]. Newly syn-
thesized HFE binds to beta 2 - macroglobulin, an 
event necessary for its expression on the cell surface 
and endosome membranes, where it interacts with 
transferrin receptor 1 (TfR1), the major receptor for 
transferrin. By disrupting a disulfide bond in HFE that 
is critical for its binding to beta 2 -macroglobulin, the 
C282Y mutation impairs cell-surface expression of 
HFE and the interaction of HFE with TfR1. 
TfR2 (transferrin receptor type 2) differs from 
TfR1 in its affinity in vitro for transferrin (1/25 to 
1/30 as strong), its high level of expression on he-
patocytes, and the fact that its expression is not 
down- regulated by hepatic iron overload [4, 7]. 
Hepcidin is synthesized by hepatocytes in response 
to both inflammatory stimuli and iron overload. It 
has been hailed as “the iron-regulatory hormone,” 
although the mechanisms underlying its effects are 
unclear. Other mutation in HFE have also describes, 
for example of a mutation in which aspartic acid 
replace histidine at position 63 (H63D), or cysteine 
replaces serine at position 65 (S65C) [1, 3, 6]. 
The phenotypic aspect of hemochromatosis
Whether a clinically asymptomatic patient with 
elevated iron levels should be classified as having HH 
is currently an issue of debate. Some investigators 
have proposed a case definition for HH comprising 
a sustained elevation in serum ferritin levels (>200 
μg/l in women and >300 μg/l in men) and transferrin 
saturation (>45% in women and >50% in men) in the 
absence of any other risk factors for iron overload [4, 
6]. This approach has the advantage of simplicity, but it 
would probably identify a number of patients who do 
not have iron overload. Other researchers insist that 
iron overload should be documented and quantified 
by liver biopsy [1, 2]. The pattern of iron distribution 
might be helpful in defining the cause of disease. The 
hepatic iron index (hepatic iron concentration divided 
by patient age) was devised before genetic testing, 
and originally used to differentiate patients with 
alcoholic siderosis from those with HH. Subsequent 
studies using genetic testing, however, have shown 
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that many patients with early hemochromatosis do 
not have an elevated hepatic iron index (>1.9), and 
that patients with other types of iron overload do 
have an elevated hepatic iron index [5, 6]. 
The patients with HH should have a constella-
tion of clinical signs and symptoms. The association 
of any symptoms of HH with elevated iron levels 
or C282Y homozygosity has, however, come under 
increased scrutiny. Patients with bronze diabetes 
probably represent <1% of all HH patients, and 
studies have shown that the prevalence of diabetes 
is similar in both C282Y homozygous and control 
populations. Other symptoms associated with HH, 
such as fatigue and arthralgia, are nonspecific and 
very common in the general population [6, 7, 8].
Table 1
Methods for iron overload assessment
Methods for iron overload assessment according to the 
type of evaluation
A Clinical features: signs and symptoms
B Serum markers: iron; ferritin; transferrin, transferrin saturation
C Tissue iron concentration: liver biopsy
D Iron toxicity markers: non transferrin bound iron, labile plasma iron; markers of oxidative damage; liver fi brosis
E Iron balance calculation: iron load with transfusions; iron removal by phlebotomy; iron excretion by chelators.
Liver disease in HH
Thanks to increasingly early diagnosis, the clas-
sic triad of cirrhosis, bronze skin and diabetes is now 
rare in adult-onset HH [2, 3]. The most common symp-
toms at presentation in middle-aged adults are now 
fatigue, malaise, arthralgia sometimes associated with 
hepatomegaly or slightly increased aminotransferase 
levels. In addition, patients commonly present with 
increased transferrin-saturation values, which are 
sometimes found even in the absence of symptoms 
[4, 5]. Increasing serum ferritin levels herald iron ac-
cumulation in the tissues, and values above 1000 ng/
ml may indicate underlying liver cirrhosis in persons 
homozygous for the C282Y mutation, regardless of 
their age or serum liver-enzyme levels [6, 7]. 
In the early stages of HH iron is located inside 
the hepatocytes in the biliary pole of the cell. Over 
time the iron overload increases leading to peroxi-
dation of iron dependent lipids causing damage and 
periportal hepatocellular death (siderotic necrosis). 
Cirrhosis develops when the hepatic concentration 
surpasses 400 mmol/g [3, 8]. Of all of the putative 
symptoms of HH, liver disease is the most consis-
tently identified abnormality. Many patients with 
liver disease are, however, asymptomatic—even 
those with hepatic fibrosis. I believe that I’d better 
describe the involvement of liver in HH by presenting 
a real clinical case. 
Table 2
Case with hereditary hemochromatosis
CLINICAL CASE
A 45 year old male patient came to the emergency service 
after three days of melena and massive hematemesis. He had 
a record of diabetes mellitus treated with insulin for 6 years 
with periodic check-ups.  Patient was admitted in generally 
bad condition with generalized mucocutaneous paleness, but 
patient was conscious and alert. Blood Pressure 90/60; HR 96/
min; RR 20/min; Cardiopulmonary assessment: Satisfactory; 
Abdomen: was found by percussion – hepatospleenomegaly; no 
ascites and collaterals. Extremities: No edema.
The patient was initially medicated with crystalloid and given 
a transfusion of 3 units of packed red blood cells (PRBCs). 
Omeprazole infusions achieved hemodynamic stability.
Personal Medical Record: Patient was hospitalized for 
chronic hepatitis (viral markers for hepatitis A, B, C was 
negative) two years prior to admission. 
Family Medical Record: Father and paternal uncle died of 
cirrhosis before they were 50 years old. Brother and sisters 
are reported to be healthy.
Epidemiologic Records: occupation - mason. No contact with 
toxics, no transfusions, no acute hepatitis, occasional smoker. 
Examinations:  anemia (Hb 78 g/l), prothrombin 55, INR 2.36, 
hyperglycemia (8.7 mmol/l), decresed total proteins (59 g/l), 
hypoalbuminemia (24 g/l), increased activity of ALT (96 U/L) 
and AST (74 U/L), alkaline phosphatase, bilirubin and gamma 
GT was normal. Autoimmune markers: ANA AMA, antiDNA 
– negative; Serological viral markers: HBsAg, anti HBs and 
antiHBcor total - negative, anti-HAIgM negative, anti HVC 
IgM – negative; anti HEV IgM – negative; He had normal 
serum ceruloplasmin and serum copper levels, urine copper of 
18 ng/ml. Serum iron: 187 mg/dl (59 – 158); Ferritin: 1144 
ng/dl (9 – 120); Saturation percentage of transferrin 96.3% 
(12 – 36).
A high digestive endoscopy was performed with a fi nding of 
esophageal varices. Band ligation (using #3 bands) was then 
performed starting from the cardia. 
A sonogram showed hepatospleenomegaly. The gall bladder, 
intrahepatic and extra hepatic bile ducts, aorta and cava were 
all normal. 
Fibrotest showed fi brosis F4 (confi rmed cirrhosis).
A preliminary diagnosis: Liver cirrhosis secondary 
hereditary hemochromatosis?
The patient has participated in a screening study, and 
was found to have the genes for hemochromatosis (C282Y 
homozygote).
The defi nitive diagnosis: Hereditary hemochromatosis 
(homozygote by C282Y HFE) with liver cirrhosis, Child-
Pugh B (9 p.).
Management of HH. Literature review and dis-
cussion our case
HH is perceived be a rare condition, reflected 
in the estimate that only about one in 10000 people 
are diagnosed with the condition [1, 2, 9]. In reality, 
HH is the most genetic condition known in people 
of European descent. It is estimated that one in 200 
people with European ancestry have the typical ge-
netic pattern associate with this condition [3, 4]. The 
discrepancy in the rates of diagnosis versus preva-
lence of positive gene tests for HH can be explained 
by two causes. First, not all people who are C282Y 
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homozygotes go on to develop evidence of iron 
overload. It is estimated that 50% of these women 
and 50–90% of this men will express the genes as 
evidenced by high serum iron tests. Second, as the 
symptoms are nonspecific, many cases of HH may 
go undiagnosed. 
To suspect HH when have: elevation in serum 
ferritin levels (>200 μg/l in women and >300 μg/l 
in men) and transferrin saturation (>45% in women 
and >50% in men) in the absence of any other risk 
factors for iron overload [5, 8, 9]. 
Case: Abnormally high levels of ferritin were found 
in our patient, while the transferrin level was found to 
be at the point of saturation. A preliminary diagnosis 
of HH was established. This patient does not need a 
liver biopsy for diagnostic purposes, as the gene test 
has already revealed that he has HH. Liver biopsy is 
currently most important for the diagnosis non-HFE 
related iron overload in patients with concomitant risk 
factors. Presence of cirrhosis in our patient decreases 
life expectancy, and increase risk of hepatocellular 
carcinoma about 200-fold as compared to normal 
subjects.  In different series 25% to 50% of those 
diagnosed with HH are diagnosed when they have 
cirrhosis. This demonstrate the absence of specific 
symptoms and signals that would cause suspicion 
of the disease and a diagnosis of the disease, and 
presented case reflected this situation. 
Treatment
Patients with HH should undergo therapeutic 
phlebotomy weekly (as tolerated). Target levels of 
phlebotomy should be a ferritin level of 50-100 μg/L 
[4, 6, 8]. In the absence of indicators suggestive of sig-
nificant liver disease (ALT, AST elevation), C282Y ho-
mozygotes who have an elevated ferritin (but <1000 
μg/L) should proceed to phlebotomy without a liver 
biopsy. Patients with end-organ damage due to iron 
overload should undergo regular phlebotomy to the 
same endpoints as indicated above. Phlebotomy has 
been found to be highly effective therapy for HH, 
preventing morbidity while promoting normal lon-
gevity. Symptoms may improve differentially during 
treatment. The strongest supporting evidence for a 
beneficial effect of phlebotomy is the improvement 
of liver fibrosis that has been demonstrated on serial 
liver biopsies in hemochromatosis patients [3, 6, 7]. 
Maintenance therapy is even less established 
following iron depletion, and many patients will 
not demonstrate any evidence of iron accumulation 
after many years of observation. Many patients enjoy 
the concept of continuous therapy for hemochro-
matosis and these patients can be encouraged to 
be voluntary blood donors several times per year. If 
they are ineligible, an annual ferritin determination 
is a reasonable alternative to guide maintenance 
therapy [2, 4, 5]. 
Case: Which clotting time corrected, our patient 
were managed with biweekly phlebotomies until levels 
of Hb 100-120 g/l. 
Iron chelation (Deferoxamine, Deferiprone) are 
the prevention of iron-related complications, the ma-
intenance of safe tissue iron levels and the reversal of 
iron-related complications [7, 8]. Hemochromatosis 
is a common and relatively simple genetic disease to 
diagnose and treat. It can be diagnosed and treated 
by family physicians using transferrin saturation, 
serum ferritin and C282Y genetic testing.
Conclusion
HH is a common genetic disease leading to ac-
cumulation of iron in the body, most notably in the 
liver. Many questions remain regarding the optimal 
screening strategy for HHC, the need for liver biopsy, 
the role of HFE genotyping, and the relationship 
between HFE genotype and clinical measures of iron 
stores. The prevalence of phenotypic HH, the excess 
mortality of liver cirrhosis, the quality of life in non-
cirrhotic HH patients, and the fractions of patients 
compliant with treatment were the most important 
variables in the sensitivity analysis.
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